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ABSTRACT: The worldwide incidence of fatty liver disease
continues to rise, which may account for concurrent increases
in the frequencies of more aggressive liver ailments. Given the
existence of histologically identical fatty liver disease subtypes,
there is a critical need for the identification of methods that
can classify disease and potentially predict progression.
Herein, we show that a panel of protein kinase chemosensors
can distinguish fatty liver disease subtypes. These direct
activity measurements highlight distinct differences between
histologically identical fatty liver diseases arising from diets
rich in fat versus alcohol and identify a previously unreported
decrease in p38α activity associated with a high-fat diet. In addition, we have profiled kinase activities in both benign (diet-
induced) and progressive (STAM) disease models. These experiments provide temporal insights into kinase activity during
disease development and progression. Altogether, this work provides the basis for the future development of clinical diagnostics
and potential treatment strategies.
Nonalcoholic fatty liver disease (NAFLD) is a metabolicspectrum disorder characterized by accumulation of >5%
fat by weight in the liver.1 This disease spectrum is
characterized by morphological changes in the liver such as
accumulation of fat associated with inflammation, known as
nonalcoholic steatohepatitis (NASH), and the eventual
development of fibrosis followed by hepatocellular carcinoma
(HCC) (Figure 1A).2 Worldwide NAFLD incidence has
reached alarming levels, with an estimated 25% of the
population afflicted by this disease (24% in the United States),
with the highest incidences in the Middle East (32%) and
lowest incidences in Africa (14%).3 The projected direct
medical cost in the United States alone on a per annual basis is
predicted to be $103 billion.4 Diagnosis of NAFLD can be
complicated due to the existence of a histologically identical
disease known as alcoholic fatty liver disease (AFLD).5,6
Though histologically identical, these two diseases arise from
significantly different behaviors, namely, the consumption of
alcohol (AFLD) or high-calorie diets rich in sugar, oils, and
fats (NAFLD). Unfortunately, the clinical definition of
significant alcohol consumption remains controversial;6
leading to issues in distinguishing AFLD versus NAFLD
based solely on histology and self-reported alcohol con-
sumption. Thus, methodologies capable of parsing NAFLD
from AFLD are needed. In this regard, one-step direct activity
assays provide increased throughput and reduced assay time
compared to traditional approaches such as Western blotting.
Ultimately, such relatively low-cost and rapid analysis
techniques could also be utilized in the clinical setting to
inform personalized treatment strategies.
While simple steatosis in NAFLD is generally benign, a
growing body of evidence suggests that individuals with NASH
are at higher risk for the development of nonviral HCC.7
Indeed, recent statistics indicate dramatic increases in both
liver cancer rates and deaths in the United States.8,9 One
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potential cause of this observation is the progression of
NAFLD to HCC (Figure 1A). Due to the prevalence of
NAFLD in the general population, there is also a need for the
identification of markers associated with disease progres-
sion.10,11
To begin to address these issues, we hypothesized that
alterations in protein kinase activity could be used to
distinguish NAFLD from AFLD and provide insights into
pathways associated with disease progression. Several elegant
chemical biology tools have been developed to probe kinase
function and activity in biological samples.12−19 Here, we
chose to employ a panel of direct, kinase chemosensors based
on the phosphorylation-sensitive sulfonamido-oxine (Sox)
fluorophore developed by the Imperiali laboratory.20,21
Figure 1. Profiling changes in fatty liver signaling using a panel of validated CSox activity probes for protein kinases. (A) Although several factors
contribute to the development of NAFLD, the common histological outcome is accumulation of fat in the liver. In certain patients with underlying
metabolic disorders, NAFLD can progress to more aggressive disease states such as NASH, fibrosis, and ultimately HCC. The estimated percentage
of patient progression is given above the arrows, adapted with permission from ref 2. (B) A nonphosphorylated CSox substrate has a low affinity for
Mg2+ and weak fluorescence (left). Upon the addition of a phosphate by a kinase, the affinity of the sensor for Mg2+ increases, leading to a
concurrent increase in fluorescence (middle). This increase in fluorescence can be plotted as a function of time and is proportional to the enzymatic
activity of the kinase (right). (C) Panel of CSox-based activity sensors that have been validated for the indicated kinase in unfractionated lysates
obtained from liver hepatocytes. In certain cases, probes contain synthetic linkers (AOO, 8-amino-3,6-dioxaoctanoic acid) or protein domains
(PNT domain S46-K138). Canonical pathways are given, and CSox is colored blue with the site of phosphorylation chlored red. (D) Workflow for
the analysis of kinase activities in normal vs fatty livers. Liver samples are homogenized and normalized to protein content. Homogenates are then
run in parallel against the panel of kinase activity probes, and the activities of each kinase can then be compared in normal (blue) and fatty liver
(red) samples to provide a signature of the disease state.
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Importantly, Sox-based probes are capable of directly reporting
on kinase enzymatic activity in real-time using a straightfor-
ward fluorescence readout in unfractionated tissue homoge-
nates.22,23 Sox displays chelation-enhanced fluorescence
(CHEF) upon binding to Mg2+. Proximal enzymatic
installation of a phosphoryl group in a peptide sequence
labeled with Sox dramatically increases the affinity of the Sox-
containing peptide for Mg2+. Thus, Sox peptides can be used to
directly visualize protein kinase enzymatic activity through
CHEF (Figure 1B). First-generation Sox sensors relied upon a
β-turn motif to correctly orient the Sox fluorophore and the
site of phosphorylation for subsequent Mg2+ binding. More
recently, second-generation Sox sensors that incorporate a
single unnatural amino acid mutation consisting of a cysteine
residue alkylated with the Sox fluorophore have been
developed (CSox) (Figure 1B).24 When placed proximal to a
site of phosphorylation (±2 residues), CSox allows for CHEF
upon phosphorylation, enabling the design of more efficient
kinase substrates through incorporation of both N- and C-
terminal recognition elements. Panels of CSox-based probes
have been utilized to fingerprint mixtures of mitogen-activated
protein kinases (MAPKs) in vitro.25 Additional selectivity for a
kinase can be imparted through the incorporation of docking
domains to drive binding affinity and/or the use of inhibitors
to suppress off-target activity.22,23 Indeed, these approaches
have yielded validated probes for p38α, MK2, JNK1/2/3,
ERK1/2, Akt, and PKA that can be used to selectively report
on kinase activity in unfractionated lysates obtained from liver
hepatocytes (Figure 1C).26−28 Inspired by previous work
demonstrating the ability to fingerprint biological samples
based on kinase activity,29 we show that NAFLD and ALFD
can be parsed on the basis of differences in kinase activity as
assessed by this panel of CSox-based chemosensors. In
addition, we identify factors that may distinguish benign and
progressive NAFLD as well as provide a temporal map of
kinase activity during progression of NAFLD to HCC (Figure
1D). These results provide a rapid means to distinguish
between histologically identical fatty liver disease subtypes and
could be used as the basis for the development of diagnostic
tools.
■ MATERIALS AND METHODS
General Reagents and Procedures. All assays were
performed in 384-well, white, half-area plates (Corning, 3824)
with a total volume of 40 μL. Fluorescence data were collected
with a Bio-Tek Synergy H1 microplate reader with excitation
at 360 nm and emission at 485 nm. Assay buffer consisted of
50 mM Tris-HCl (pH 7.5 at 22 °C), 10 mM MgCl2, 1 mM
EGTA, 2 mM DTT, 0.01% Brij-35-P, and 1 mM ATP. Lysis
buffer consisted of 50 mM Tris-HCl (pH 7.5 at 22 °C), 150
mM NaCl, 30 mM NaF, 1% (v/v) Triton X-100, 2 mM EGTA,
1 mM DTT, 1% (v/v) protease inhibitor cocktail III (EMD
Millipore, 539134), and 1% (v/v) phosphatase inhibitor
cocktail III (Sigma, P0044). Detailed methods for probe
synthesis as well as tissue lysis and analysis can be found in
previously published protocols,22,23 brief descriptions of these
procedures are given below.
Probe Synthesis. All peptide sensors were synthesized
using standard Fmoc-protected solid-phase peptide synthesis
methods as previously reported.23 Sox was introduced either
through direct alkylation of on-resin peptides or through
incorporation of Fmoc-CSox. Peptide sensors were cleaved
from the resin and purified by high-performance liquid
chromatography, and their identity was verified by mass
spectrometry. The ERK1/2 sensor was prepared as described
previously,26 purified by FPLC, and confirmed by sodium
dodecyl sulfate−polyacrylamide gel electrophoresis (SDS−
PAGE).
Animal Models. For the NAFLD model, simple steatosis
was generated by feeding 200 g male Wistar rats with a high-fat
diet consisting of 60% calories from saturated, monounsatu-
rated, and polyunsaturated fatty acids (ResearchDiets,
D08060104) ad libitum for 8 weeks.5 To generate their
respective controls, rats of the same age and weight were fed a
control diet consisting of 10% calories from fatty acids
(Research Diets, D12450K) ad libitum for 8 weeks. For the
AFLD model, male Wistar rats were pair-fed with Lieber−
DeCarli control or EtOH−liquid diets that contained calories
of 18% from protein, 35% from fat, 11% from carbohydrate,
and 36% from ethanol.5 In the control diet, ethanol was
replaced isocalorically with maltodextrin.
Frozen STAM mouse tissue samples were obtained from
SMC Laboratories (Tokyo, Japan). In-house STAM tissues
were generated by injecting 2-day-old pups with a single bolus
of 0.2 mg of STZ subcutaneously. Once the mice were weaned,
they were immediately fed a high-fat diet ad libitum (BioServ
F3282) until age 6 weeks (simple steatotis), 8 weeks (NASH),
12 weeks (fibrosis), or 20 weeks (HCC). Uninjected
littermates were fed an isocaloric low-fat control diet (BioServ
F4031) over the same time courses.30
All animal protocols were reviewed by the Institutional
Animal Care and Use Committees (IACUCs) of both the
University of NebraskaLincoln and Nebraska-Western Iowa
Health Care System Research Service, both of which have been
certified by the American Association for the Accreditation of
Laboratory Animal Care (AAALAC).
Generation of Tissue Homogenates. Tissue homoge-
nates were prepared as described previously.22 Frozen liver
tissue samples were weighed and rinsed three times with ice-
cold phosphate-buffered saline. Ice-cold lysis buffer (3 μL/mg
of tissue) was added to each sample. Tissue samples were then
homogenized using a hand-held homogenizer (Omni, TH115-
PCRH) with disposable, hard tissue tips (Omni, 30750H).
Samples were incubated on ice for 15 min followed by
centrifugation at 4 °C for 5 min. The soluble fraction of each
homogenate was aliquoted, flash-frozen in liquid nitrogen, and
stored at −80 °C. The total protein content in each sample was
determined using the Bio-Rad Protein Assay Kit (Bio-Rad,
5000001) according to the manufacturer’s protocol.
Kinase Activity Assays. Assays were conducted as
described previously.22 Assays were corrected for lag times,
and slopes were calculated using the linear region of the data.
While lag times and linear regions vary between kinases,
conditions for individual kinases were identical allowing
comparison of relative activities (slopes). Each kinase was
assayed in duplicate for each animal in assay buffer using the
indicated Sox sensor for Akt (2.5 μM), ERK1/2 (5 μM), MK2
(2.5 μM), p38α (1 μM), or JNK (3 μM). The assays were
miniaturized for use in 384-well plates using a total volume of
40 μL per well. Total protein amounts for each probe were as
follows: 3.3 μg for Akt, MK2, and p38α; 6.6 μg for JNK1/2/3
and PKA; and 13.3 μg for ERK1/2. Inhibitors were included in
Akt (4 μM PKC inhibitor peptide, 4 μM calmidazolium, and 5
μM GF109203X), p38α (10 μM staurosporine), and PKA (4
μM PKC inhibitor peptide, 4 μM calmidazolium, and 5 μM
GF109203X) assays. The activity of p38α was resolved by
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background subtraction of identical assays performed in the
presence of the p38α inhibitor SB203580 (10 μM). Reaction
slopes were determined from the initial linear portion of each
assay. Heat maps of kinase activities were generated in R.
Western Blotting. Lysates were separated on 12% SDS−
PAGE gels, and proteins were transferred to a nitrocellulose
membrane. Blots were probed with primary antibodies for total
p38 (Cell Signaling, 9212) or phospho-p38 (Cell Signaling,
9215). Primary antibody binding was detected using an HRP-
conjugated goat anti-rabbit (Pierce, 32460) secondary anti-
body. Blots were visualized by enhanced chemiluminescence
(Pierce, 34075).
■ RESULTS AND DISCUSSION
NAFLD and AFLD Can Be Distinguished Using a
Panel of Kinase Activity Probes. To investigate whether
kinase activity probes could help facilitate parsing of NAFLD
and AFLD, we chose to compare activity profiles of liver
tissues obtained from animal models of NAFLD and AFLD.
Although NAFLD and AFLD livers display indistinguishable
histology (Figure S1),5 the etiology of each disease is different.
Thus, we hypothesized that underlying signaling states may
provide a basis for distinguishing NAFLD from AFLD.
Accordingly, liver homogenates from rats fed a control diet
or induced for NAFLD (n = 12) or AFLD (n = 6)
development were obtained. These homogenates were assayed
in 384-well plates using the panel of kinase activity probes
(Figure 2A,B). Comparison of these profiles clearly indicated
significant alterations in different MAPK signaling cascades in
NAFLD versus AFLD. Specifically, we observed a 44 ± 10%
increase in JNK1/2/3 activity in NAFLD samples while
ERK1/2 activity was increased by 29 ± 2% in AFLD samples.
These findings are consistent with previous reports of
increased liver-associated JNK activity and phosphorylation
in mouse models of NAFLD31,32 as well as increased levels of
phospho-ERK expression in human AFLD livers.33 In addition
to these changes, we observed a 73 ± 10% decrease in p38α
activity coupled with a 15 ± 3% decrease in the activity of its
downstream substrate, MK2, in NAFLD. To the best of our
knowledge, this decrease in the activity of p38α has not been
previously reported. Western blotting indicated a decrease in
the level of phosphorylation of total p38 (α, β, γ, and δ),
consistent with activity assays (Figure S2). These results imply
the potential dysregulation of upstream protein kinase or
phosphatase activity in NAFLD, which is currently under
investigation in our laboratory. Previous work has identified
p38 as a negative regulator of fat synthesis and storage in the
liver.34 Thus, deactivation of p38 signaling in NAFLD could
allow for the accumulation of excess fat. Regardless of the
consequences of these kinase activity perturbations, this data
set confirms existing observations and comparison of NAFLD
and AFLD kinase activities provides an activity signature that
distinguishes between these disease states (Figure 2C). In
particular, we observed statistically significant 3.6- and 1.2-fold
increases in p38α and MK2 activities, respectively, in AFLD
and an 18 ± 3% increase in PKA activity in NAFLD (Figure
2D). Thus, this panel of kinase chemosensors can be used to
readily distinguish these histologically identical disease states.
Changes in Kinase Activity in Progressive NAFLD.
Encouraged by the ability of kinase activity probes to
distinguish histologically identical liver disease states, we next
asked whether this probe panel could parse models of benign
and progressive NAFLD. Accordingly, we set out to compare
our diet-induced rat model of NAFLD, which does not
progress to more serious disease phenotypes, to the well-
established STAM mouse model of liver disease progression.30
Figure 2. Kinase activity probes reveal distinct differences between diet-induced NAFLD and AFLD. Kinase activities in normal and diseased liver
homogenates for (A) NAFLD (n = 12) and (B) AFLD (n = 6). Kinase activities are normalized to control samples. (C) Heat map showing clear
differences in NAFLD vs AFLD kinase activities. Fold change is defined as the kinase activity in the fatty liver disease (FLD) samples relative to the
corresponding control (normal) livers. (D) Statistically significant differences in p38α, MK2, and PKA activities distinguish NAFLD from AFLD. p
values from a two-tailed t test are represented by one asterisk (<0.05), two asterisks (<0.01), or three asterisks (<0.001). Error bars represent the
standard error of the mean.
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The STAM model uses a two-hit protocol of initial treatment
with streptozotocin (STZ) to induce the death of pancreatic β-
cells, mimicking type I diabetes, followed by administration of
a high-fat diet. The STAM model faithfully induces NAFLD
that progresses to HCC with essentially 100% fidelity (Figure
S3). Liver homogenates were obtained from diet-induced
NAFLD (n = 12) and STAM NAFLD (n = 5) models and
interrogated using the panel of kinase activity probes (Figure
S4A). These assays indicate clear differences in kinase signaling
associated with the progressive, STAM NAFLD model [6
weeks (Figure 3A)]. Interestingly, STAM NAFLD displayed a
5.2-fold increase in p38α activity compared to that of diet-
induced NAFLD (Figure 3B). This observation indicates that
the two-hit STAM model may lead to an increased level of
inflammatory signaling through the p38α axis, possibly
potentiating a perturbed inflammatory state leading to disease
progression. This hypothesis is currently under investigation in
our laboratory. In addition, we observed statistically significant
69 ± 11%, 18 ± 4%, and 19 ± 9% increases in MK2, Akt, and
PKA activities, respectively, in STAM NAFLD versus diet-
induced NAFLD (Figure 3B). Together, these results indicate
significant changes in inflammatory, survival, and metabolic
signaling associated with the STAM model of NAFLD and
provide a basis set for future experiments aimed at identifying
factors that may potentiate NAFLD progression as well as
approaches to block progression to NASH.
Longitudinal Kinase Activity during NAFLD Progres-
sion. To further investigate the utility of CSox-based activity
probes for profiling changes associated with NAFLD
progression, we obtained liver samples (n = 5) from the
STAM mouse model corresponding to NAFLD (6 weeks),
NASH (8 weeks), fibrosis (12 weeks), and HCC (20 weeks).
Tissue homogenates for each of these samples as well as
control animals were generated and normalized to the total
protein content. Subsequent assays using CSox-based probes
produced a temporal profile of kinase activity perturbations
during disease progression (Figure 4 and Figure S4A−D). As
expected, the activities of p38α and its downstream effector,
MK2, were coupled over time during disease progression
(Figure 4 and Figure S4E). Activities of both enzymes peaked
in NASH with 56 ± 40% and 57 ± 16% increases observed in
p38α and MK2 activities, respectively, relative to control
samples. PKA and Akt activities began elevated by 21 ± 9%
and 12 ± 4%, respectively, in NAFLD and decreased in a linear
fashion over time (Figure 4 and Figure S4F). Lastly, JNK1/2/3
activity displayed an oscillatory profile beginning with a 37 ±
26% increase in NAFLD and ending with a 52 ± 24% decrease
in HCC (Figure 4 and Figure S4G). Taken together, this
temporal profile provides a starting point for the analysis of
kinase signaling dynamics during NAFLD progression. Current
efforts are focused on utilizing additional CSox-based probes
for kinases22,23,35,36 and phosphatases37−40 as well as small
molecule probes for reactive oxygen species41,42 to further
define potential changes associated with disease progression.
■ CONCLUSION
We have demonstrated the utility of panels of CSox-based
kinase activity sensors for distinguishing histologically identical
liver disease subtypes. These proof-of-principle experiments
indicate the ability to parse NAFLD and AFLD as well as
benign and progressive NAFLD. An initial temporal profile of
kinase activity during NAFLD progression provides a starting
point for further analysis of signaling changes associated with
disease progression. The availability of a rapid, low-cost
screening platform capable of distinguishing NAFLD from
AFLD enables the potential development of clinical diagnostics
Figure 3. Changes in kinase activity differentiate diet-induced NAFLD and progressive STAM NAFLD. (A) Heat map showing differences in
kinase enzymatic activity in diet-induced NAFLD vs STAM NAFLD (6 weeks). Fold change is defined as the kinase activity in the fatty liver disease
(FLD) samples relative to the corresponding control (normal) livers. (B) Statistically significant differences in p38α, MK2, Akt, and PKA activities
are observed in diet-induced NAFLD vs STAM NAFLD. p values from a two-tailed t test are represented by one asterisk (<0.05), two asterisks
(<0.01), or three asterisks (<0.001). Error bars represent the standard error of the mean.
Figure 4. Heat map depicting temporal changes in kinase activity in
the STAM model from NAFLD through HCC (treatment for 6−20
weeks). Fold change is defined as the kinase activity in the STAM
livers relative to control livers.
Biochemistry Article
DOI: 10.1021/acs.biochem.9b00547
Biochemistry 2019, 58, 3911−3917
3915
and the identification of pathways for further investigation
using small molecule inhibitors.
■ ASSOCIATED CONTENT
*S Supporting Information
The Supporting Information is available free of charge on the
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NAFLD livers display decreased phosphorylation of p38. Reduced phosphorylation of the 
p38 (P-p38) activation loop is observed in NAFLD (High Fat) versus control (Normal) livers. 
Total p38 staining indicates that levels of p38 do not change appreciably in each sample. Total 
p38 and P-p38 antibodies recognize , , , and  isoforms of p38. β-actin staining 
demonstrates equivalent protein loading in each lane.
S4
Figure S3
Progression of the STAM model through increasingly severe stages of liver disease. H&E 
staining of livers from animals fed a control diet as well as STAM animals at varying time points 




Changes in kinase activity in the STAM model. Kinase activities for STAM NAFLD (A, n = 5), 
NASH (B, n = 5), fibrosis (C, n =5), and HCC (D, n = 5) relative to control animals (n = 5) are 
shown. Significant increases in MK2 (43%), Akt (12%), and PKA (21%) activities are observed 
in STAM NAFLD. A significant increase in MK2 activity in NASH (57%) and HCC (31%) was 
observed. Kinase activities for MK2 and p38α (E), Akt and PKA (F), and JNK (G) are clustered 
according to similar trends in activity during disease progression. STAM (n = 5) samples are 
normalized to control animals (n = 5). Activities are shown versus time for STAM NAFLD (6 
week), NASH (8 week), fibrosis (12 week), and HCC (20 week) samples. P-values from a two-
tailed t-test are represented by * (< 0.05) or ** (< 0.01). Error bars represent sem.
